Replies to post #333837 on NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

ATLnsider,

Those 17 missing SOC/placebo patients might have something to do with all the changes we have seen from 2015 up until now don’t you think? Lol. Best wishes.

[Poor Man -]

The company has at least two or three obstacles before uplisting. Given their history, they first need to resolve any open issues they have with the SEC - this might be the real cause for the delayed release of the 10Q. They’ll also need to improve corporate governance and managerial controls, including at minimum the hiring of a separate CFO. Lastly, they need to maintain a minimum share price above $3 or $4 depending on the criteria for 90 days.

So, even if they want to uplist, it might take 6 months or more since we’re not even at TLD right now. But they certainly don’t seem to be acting like a company preparing to uplist. Maybe they don’t expect to be around much longer after TLD? A buyout would be nice.

Splurged on TG, and had some genuine NY cheesecake - man that stuff is good. (Bought more shares today, since I wasn’t really paying for dinner.)

NWBio should be able to submit their application to uplist soon. Donohoe Advisory Associates has extensive experience helping companies uplist from the OTC to either the NYSE, NASDAQ or AMEX.

[pgsd]

Agreed also, whilst it does not necessarily mean that [at this time] a BO is off the table but if they are planning to uplist it may suggest a partnership rather than BO.